In vitro characterization of the drug-drug interaction potential of catabolites of antibody-maytansinoid conjugates

Drug Metabolism and Disposition

Volumn 40, Issue 10, 2012, Pages 1927-1934

  Davis, John A ^a   Rock, Dan A ^a   Wienkers, Larry C ^a   Pearson, Josh T ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; MAYTANSINE; METHYL N2 DEACETYL N2' (3 MERAPTO 1 OXOPROPYL)MAYTANSINE; METHYL N2 DEACETYL N2' (4 MERCAPTO 4 METHYL 1 OXOPENTYL)MAYTANSINE; N SUCCINIMIDYL 4 (N MALEIMIDOMETHYL)CYCLOHEXANE 1 CARBOXYLATE N2 DEACETYL N2' (3 MERAPTO 1 OXOPROPYL)MAYTANSINE CONJUGATE; N2 DEACETYL N2' (3 MERAPTO 1 OXOPROPYL)MAYTANSINE; N2 DEACETYL N2' (4 MERCAPTO 4 METHYL 1 OXOPENTYL)MAYTANSINE; UNCLASSIFIED DRUG;

AEROBIC METABOLISM; ARTICLE; CATABOLISM; CONTROLLED STUDY; DRUG CONJUGATION; DRUG STRUCTURE; ENZYME INACTIVATION; IN VITRO STUDY; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DEXTROMETHORPHAN; DEXTRORPHAN; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; IMMUNOCONJUGATES; KINETICS; MAYTANSINE; MICROSOMES, LIVER; PACLITAXEL; RECOMBINANT PROTEINS; RISK ASSESSMENT;

EID: 84866444321     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.046169     Document Type: Article

References (33)

1. Al-Katib AM, Aboukameel A, Mohammad R, Bissery MC, and Zuany-Amorim C (2009) Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma. Clin Cancer Res 15:4038-4045.
2. Baer BR, Wienkers LC, and Rock DA (2007) Time-dependent inactivation of P450 3A4 by raloxifene: identification of Cys239 as the site of apoprotein alkylation. Chem Res Toxicol 20:954-964. (Pubitemid 47035350)
3. Beijnen JH and Schellens JH (2004) Drug interactions in oncology. Lancet Oncol 5:489-496. (Pubitemid 39069399)
4. Blower P, de Wit R, Goodin S, and Aapro M (2005) Drug-drug interactions in oncology: why are they important and can they be minimized? Crit Rev Oncol Hematol 55:117-142. (Pubitemid 40981915)
5. Boudreaux M, Prokop S, Patel S, and Zalikowski J (2012) Bioanalytical support for AMG XXX TK studies. 60th ASMS Conference on Mass Spectrometry and Allied Topics; 2012 May 20-24; Vancouver, Canada. American Society for Mass Spectroscopy, Santa Fe, New Mexico.
6. Burris HA 3rd, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, Tan-Chiu E, Krop IE, Michaelson RA, Girish S, et al. (2011) Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 29:398-405.
7. Chari RV (1998) Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy. Adv Drug Deliv Rev 31:89-104.
8. Chari RV (2008) Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res 41:98-107.
9. Erickson HK, Park PU, Widdison WC, Kovtun YV, Garrett LM, Hoffman K, Lutz RJ, Goldmacher VS, and Blättler WA (2006) Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 66:4426-4433.
10. Erickson HK, Widdison WC, Mayo MF, Whiteman K, Audette C, Wilhelm SD, and Singh R (2010) Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Bioconjug Chem 21:84-92.
11. Gertz M, Kilford PJ, Houston JB, and Galetin A (2008) Drug lipophilicity and microsomal protein concentration as determinants in the prediction of the fraction unbound in microsomal incubations. Drug Metab Dispos 36:535-542. (Pubitemid 351397979)
12. Girish S, Gupta M, Wang B, Lu D, Krop IE, Vogel CL, Burris Iii HA, LoRusso PM, Yi JH, Saad O, et al. (2012) Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother Pharmacol 69:1229-1240.
13. Gratus C, Damery S, Wilson S, Warmington S, Routledge P, Grieve R, Steven N, Jones J, and Greenfield S (2009a) The use of herbal medicines by people with cancer in the UK: a systematic review of the literature. QJM 102:831-842.
14. Gratus C, Wilson S, Greenfield SM, Damery SL, Warmington SA, Grieve R, Steven NM, and Routledge P (2009b) The use of herbal medicines by people with cancer: a qualitative study. BMC Complement Altern Med 9:14.
15. Gupta M, Lorusso PM, Wang B, Yi JH, Burris HA 3rd, Beeram M, Modi S, Chu YW, Agresta S, Klencke B, et al. (2012) Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer. J Clin Pharmacol 52:691-703.
16. Hanigan MH (2009) Over-the-counter medications and cancer patients: growing awareness of drug-drug interactions. Expert Opin Drug Metab Toxicol 5:105-107.
17. Ikeda H, Hideshima T, Fulciniti M, Lutz RJ, Yasui H, Okawa Y, Kiziltepe T, Vallet S, Pozzi S, Santo L, et al. (2009) The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res 15:4028-4037.
18. Kellogg BA, Garrett L, Kovtun Y, Lai KC, Leece B, Miller M, Payne G, Steeves R, Whiteman KR, Widdison W, et al. (2011) Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage. Bioconjug Chem 22:717-727.
19. Krop IE, Beeram M, Modi S, Jones SF, Holden SN, Yu W, Girish S, Tibbitts J, Yi JH, Sliwkowski MX, et al. (2010) Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 28:2698-2704.
20. Lapusan S, Vidriales MB, Thomas X, de Botton S, Vekhoff A, Tang R, Dumontet C, Morariu-Zamfir R, Lambert JM, Ozoux ML, et al. (2012) Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. Invest New Drugs 30:1121-1131.
21. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blättler WA, Lambert JM, Chari RV, Lutz RJ, et al. (2008) Targeting HER2-positive breast cancer with trastuzumab- DM1, an antibody-cytotoxic drug conjugate. Cancer Res 68:9280-9290.
22. Meijerman I, Beijnen JH, and Schellens JH (2006) Herb-drug interactions in oncology: focus on mechanisms of induction. Oncologist 11:742-752. (Pubitemid 44157562)
23. Pearson JT, Wahlstrom JL, Dickmann LJ, Kumar S, Halpert JR, Wienkers LC, Foti RS, and Rock DA (2007) Differential time-dependent inactivation of P450 3A4 and P450 3A5 by raloxifene: a key role for C239 in quenching reactive intermediates. Chem Res Toxicol 20:1778-1786.
24. Riechelmann RP and Del Giglio A (2009) Drug interactions in oncology: how common are they? Ann Oncol 20:1907-1912.
25. Scripture CD and Figg WD (2006) Drug interactions in cancer therapy. Nat Rev Cancer 6:546-558. (Pubitemid 43980543)
26. Senter PD (2009) Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol 13:235-244.
27. Smith SV (2005) Technology evaluation: huN901-DM1, ImmunoGen. Curr Opin Mol Ther 7:394-401.
28. Sparreboom A, Cox MC, Acharya MR, and Figg WD (2004) Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol 22:2489-2503. (Pubitemid 41115408)
29. Sun X, Widdison W, Mayo M, Wilhelm S, Leece B, Chari R, Singh R, and Erickson H (2011) Design of antibody-maytansinoid conjugates allows for efficient detoxification via liver metabolism. Bioconjug Chem 22:728-735.
30. Widdison W, Wilhelm S, Veale K, Erickson H, Audette C, Leece B, Jones G, and Chari R (2010) Detoxification of metabolites from antibody-maytansinoid conjugates by human liver microsomes. Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 April 17-21; Washington, DC. American Association for Cancer Research, Philadelphia, PA.
31. Widdison WC, Wilhelm SD, Cavanagh EE, Whiteman KR, Leece BA, Kovtun Y, Goldmacher VS, Xie H, Steeves RM, Lutz RJ, et al. (2006) Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem 49:4392-4408. (Pubitemid 44036683)
32. Wienkers LC and Stevens JC (2003) Cytochrome P450 reaction phenotyping, in Drug Metabolizing Enzymes: Cytochrome P450 and Other Enzymes in Drug Discovery and Development (Lee JS, Obach RS, and Fisher MB eds) pp 255-300, Fontis Media S.A. & Marcel Dekker, Inc., New York.
33. Zhang H, Davis CD, Sinz MW, and Rodrigues AD (2007) Cytochrome P450 reaction-phenotyping: an industrial perspective. Expert Opin Drug Metab Toxicol 3:667-687. (Pubitemid 351320636)